



# LIFE SCIENCE REIT

## CREATING SPACE FOR SCIENCE

### RESULTS PRESENTATION

FOR THE YEAR ENDED 31 DECEMBER 2022



**DISCLAIMER:** For any retail investor who may consider this product, it is recommended that they seek independent professional advice before making an investment

## DISCLAIMER AND NOTICES TO INVESTORS IN THE UNITED KINGDOM AND EUROPE

---

The information contained in this document and any communication or documents or other materials distributed at or in connection with the document (together, the "Presentation") is confidential and is being made to or directed to in the United Kingdom only to (i) persons who have professional experience in matters relating to investments (being "investment professionals" within the meaning of Article 19 of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "FPO")) or (ii) persons falling within Article 49(2) ("high net worth companies, unincorporated associations etc") of the FPO or (iii) persons who are otherwise permitted by law to receive it (all such persons being "Relevant Persons"). This presentation may not be disseminated, distributed or used without the prior written consent of Ironstone Asset Management Ltd. and G10 Capital Limited (the "Companies"). The information contained in the Presentation is not intended to be viewed by, passed on or distributed (directly or indirectly) to, any other category of persons. Any investment or investment activity to which the Presentation relates is available only to Relevant Persons and will be engaged in only with Relevant Persons. This Presentation must not be acted or relied upon by persons who are not Relevant Persons. Ironstone Asset Management Ltd. is an Appointed Representative of G10 Capital Limited, which is authorised and regulated by the Financial Conduct Authority

No undertaking, representation, warranty or other assurance is given, and none should be implied, as to, and no reliance should be placed on, the accuracy, completeness or fairness of the information or opinions contained in the Presentation. The information contained in the Presentation is subject to completion, alteration and verification nor should it be assumed that the information in the Presentation will be updated. The information contained in the Presentation has not been verified by G10 Capital Limited ("G10") or any of its associates or affiliates. Opinions and estimates constitute the Companies' judgment and should be regarded as indicative, preliminary, strictly non-binding and for illustrative purposes only. All example statements and any indicative terms and features of any solution given are strictly indicative and may be based on certain implicit and explicit assumptions which the Companies may or may not be able to disclose at the time of the Presentation and which will need verification in any specific case.

In particular, but without prejudice to the generality of the foregoing, any forecasts, opinions, estimates and projections contained in the Presentation constitute the judgment of the Companies and are provided for illustrative purposes only. Such forecasts, opinions, estimates and projections involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forecasts, opinions, estimates and projections. Accordingly, no representation or warranty (express or implied) is or will be made or given in relation to, and (except in the case of wilful fraud) no responsibility or liability is or will be accepted by the Companies or any of its directors, officers, employees, agents or advisers in respect of, such forecasts, opinions, estimates and projections or their achievement or reasonableness. Relevant Persons of the Presentation must determine for themselves the reliance (if any) that they should place on such forecasts, opinions, estimates and projections. Further, no representation as to the actual value which may be received in connection with a transaction is given, nor the legal, tax or accounting effects of consummating a transaction.

Information contained in the Presentation may not be distributed, published or reproduced in whole or in part or disclosed by Relevant Persons to any other person. The distribution of any document provided at or in connection with the Presentation in jurisdictions other than the United Kingdom may be restricted by law and therefore persons into whose possession any such documents may come should inform themselves about and observe any such restrictions. In particular, information contained within the Presentation is not for distribution in or into the United States, Canada, Australia, the Republic of Ireland, Japan or South Africa. Any failure to comply with these restrictions may constitute a violation of the securities law of such jurisdictions.

The information contained in the Presentation has not been approved by the Financial Conduct Authority. This Presentation does not constitute, or form part of, any offer of, or invitation to apply for, securities nor shall it, or the fact of its distribution, form the basis of or be relied upon in connection with any contract or commitment to acquire any securities. The information contained in the Presentation has been prepared to assist Relevant Persons in making their own evaluations and does not purport to contain all of the information that recipients of the Presentation who are considering acquiring or subscribing for shares, bonds or other securities may need or desire. In all cases, Relevant Persons should conduct their own investigation and analysis of the data in the Presentation. The Presentation should not be considered a recommendation by the Companies' or any of its directors, officers, employees, agents or advisers in connection with any purchase of or subscription for securities. Any references in The Presentation to "our" refer to Life Science REIT plc.

## DISCLAIMER AND NOTICES TO INVESTORS IN THE UNITED KINGDOM AND EUROPE

---

The following risks are a non-exhaustive list of risks associated with the Company. Investors should take independent financial advice prior to investing in the Company.

- Performance – The performance of the Company would be adversely affected by a downturn in the UK property market in terms of market value or a weakening of rental yields.
- Operational Performance – Both rental income and market value of the properties acquired by the Company will be affected by the operational performance of the properties or the related business being carried on in the property and the general financial performance of the tenants.
- Failure to Achieve Investment Objectives – The ability of the Company to achieve its investment objectives depends on the ability of the Investment Advisor to identify, select and arrange for the execution of investments which offer the potential for satisfactory returns. The underperformance of the Investment Advisor could have a material adverse affect on the Company's financial condition and operations.
- COVID-19 – The COVID 19 pandemic and associated government measures has had and is likely to continue to have a significant impact on the Company, and the ultimate impact is dependent on the duration and extent of the pandemic and is therefore not yet known.
- Competition – The Company may face significant competition from other UK or foreign property investors. The existence of such competition may have a material adverse impact on the Company's ability to acquire properties and to secure tenants for its properties at satisfactory rental rates and on a timely basis.
- Regulatory Compliance – The Company cannot guarantee that the Group will maintain continued compliance with all of the REIT conditions. If the Company fails to maintain its REIT status, its rental income and capital gains may be subject to UK taxation which could have a material impact on the financial condition of the Company.
- Borrowing – The Company intends to use borrowings to acquire further properties and those borrowings may not be available at the appropriate time or on suitable terms. If borrowings are not available on suitable terms or at all this will have a material adverse impact on the returns to Shareholders and in particular the level of dividends paid. Whilst the use of borrowings should enhance the NAV where the value of the Company's underlying assets is rising, it will have the opposite effect where the underlying asset value is falling. In addition, in the event that the rental income of the Company's portfolio falls for whatever reason, the use of borrowings will increase the impact of such a fall on the net revenue of the Company.
- Development & Maintenance – Any development or refurbishment works may involve significant costs and may be adversely affected by certain restrictions. This could cause the resulting revenues to be lower than budgeted, and may cause the asset to fail to perform in accordance with the Company's investment projections, consequently impacting on the financial condition of the Company.

# AGENDA

## Presenting Team

- 1 | Key Highlights
- 2 | UK Life Science Sector
- 3 | Financial Results
- 4 | Portfolio Review
- 5 | Concluding Remarks
- 6 | Appendices



**Simon Farnsworth**  
Managing Director



**David Lewis**  
Finance Director



**Ian Harris**  
Asset Management Director

## Contact

Life Science REIT plc  
+44 (0) 203 011 2160  
Email: [contact@lifesciencereit.co.uk](mailto:contact@lifesciencereit.co.uk) | [investments@lifesciencereit.co.uk](mailto:investments@lifesciencereit.co.uk)  
<https://lifesciencereit.co.uk/>

# 01

## KEY HIGHLIGHTS

For the year ended 31 December 2022

**£213.4m**

Acquisitions  
Completed

**£150.0m**

Debt Facility  
Secured

**+£4.5m**

Additional  
Contracted Rent

**+4.7%**

LFL ERV Growth

**£3.4m**

of Rent Signed or  
with Terms  
Agreed

**+60.0%**

of Development  
Property<sup>(1)</sup> Pre-let  
or with Terms  
Agreed

KEY

31-Dec-22

27-Mar-23

Note: Past performance is not indicative of future results

(1) Includes buildings classified as 'under construction' as at 31 December 2022 i.e. Buildings 4a, 4b and 5

## KEY HIGHLIGHTS: DELIVERING ON OUR STRATEGY SET AT IPO

### Financial Results

- £315.1m NTA / 90.0p NTA per share, reduction driven by revaluation losses
- £2.5m adj. earnings; full year's income of 2021 assets and c. 7 months of 2022 assets
- 16.8% LTV following new debt and debt acquired in year, target remains 30%-40%

### Portfolio

- £387.6m of properties and development land; **all located in the Golden Triangle**
- H2 2022 absolute valuation decline significantly less than other asset classes (see p.21)
- **4.7% LFL ERV growth** driven by lab conversion and refurb projects
- Significant **reversionary potential in the let portfolio of 8.7%**<sup>(1,2)</sup> that will help offset any future outward yield shift
- Rolling Stock Yard lab fit to PC<sup>(3)</sup> by Q1 2023; second floor **pre-let at £110.0 per sq ft**
- OTP development continues; **252,000 sq ft to PC<sup>(3)</sup> in 2023**

### Sustainability

- Developed strategy and established a Sustainability Committee
- EPCs reassessment led to a **65% LFL increase in EPCs A-C** since Dec-21<sup>(4)</sup>

### Other / Post YE Events

- Move to Main Market of the London Stock Exchange on 1 December 2022
- Full repayment of Fairfield debt and drawdown of RCF in February 2023
- £3.4m of additional contracted rent signed or with terms agreed
- Declared second interim dividend of 3.0 pence per share<sup>(5)</sup>

	Full year to 31-Dec-22	Six weeks to 31-Dec-21	% Change
Adjusted Earnings	£2.5m	(£0.3m)	+£2.8m
Adjusted EPS	0.7p	(0.1p)	+0.8p
EPRA NTA	£315.1m	£350.6m	(£35.4m)
EPRA NTA per share	90.0p	100.2p	(10.2p)
Dividend per share	4.0p <sup>(6)</sup>	--	+4.0p
Loan to Value	16.8%	n/a	n/a
Property Valuation	£387.6m	£192.2m	+£195.4m
Contracted Rent	£13.8m	£9.3m	+£4.5m
ERV	£17.2m	£10.1m	+£7.1m
Completed Area	488,700 <sup>(7,8)</sup>	317,400	+171,300
Occupancy	82.0%	80.6%	+1.4%
WAULT to Expiry	6.2 yrs	6.5 yrs	(0.3 yrs)
NRY	5.2% <sup>(9)</sup>	5.0%	+0.2%



02

# UK LIFE SCIENCE SECTOR

## Structurally supported real estate

Support from  
Government &  
Private Sector

Global Leader on  
VC Funding per  
Capita

All-Time Low  
Vacancy Rates

Take-up at  
Record Highs

Lab Demand  
Exceeds Offices  
for the First Time

Insufficient  
Pipeline to Cover  
Take-up Forecast

# UK LIFE SCIENCE SECTOR: WHAT IS LIFE SCIENCES?


Life science is the branch of sciences concerned with all processes affecting living organisms



Data & AI




Healthcare



Technology



Pharmaceuticals



Quantum Computing



Research



Biomed / Gene Sequencing



Climate Change



Robotics



Agri-Tech



## UK LIFE SCIENCE SECTOR: GOVERNMENT SETS SCIENCE HIGH ON NATIONAL AGENDA

British government has set clear mission to ensure the UK is a globally recognised hub for the science industry, one of its key pillars of economic growth

### Recent Announcements & Objectives

KEY

Proposal    Actioned


<p><b>Mar-22</b></p> <p>Plans for largest ever R&amp;D budget: £20.0bn by 2024 – 2025 (+30%)</p>	<p><b>Mar-22</b></p> <p>Plans to increase total R&amp;D investment to 2.4% of GDP by 2027</p>	<p><b>Dec-22</b></p> <p>Launch of a £119m fund for overseas research collaborations</p>
<p><b>Feb-23</b></p> <p>Newly appointed Science, Innovation and Technology Secretary given dedicated seat at the Cabinet</p>	<p><b>Feb-23</b></p> <p>Creation of new Department for Science, Innovation and Technology (DSIT)</p>	<p><b>Jan-23</b></p> <p>Proposed Plan B in lieu of access to funding through Horizon, the EU’s funding programme</p>
<p><b>Mar-23</b></p> <p>Launched a £370m Science and Technology Framework to boost investment in innovation</p>	<p><b>Mar-23</b></p> <p>Tax relief offer for companies that spend +40% of total expenditure on R&amp;D</p>	<p><b>Mar-23</b></p> <p>Set up of a fast approval process for the most cutting-edge medicines and devices</p>

# UK LIFE SCIENCE SECTOR: ‘GENIUS LOCI’, OUR PRIORITY


All assets strategically located in the UK’s Golden Triangle, a life science hotspot which has shown unprecedented strength

## Portfolio Location<sup>(1)</sup>

- 1 Most important science cluster in Europe – 6,500 life science businesses in the UK<sup>(2)</sup>
- 2 Global leader on VC funding per capita – Cambridge leads the ranking and London and Oxford sit within the top 5<sup>(3)</sup>
- 3 VC reaches second highest point in history – 22% higher vs 2020 levels; 2021 was a record year<sup>(4)</sup>
- 4 Lab vacancy rates at all time lows – 0.2% in Cambridge and 2.6% in Oxford<sup>(5)</sup>
- 5 Supply shortage – 21m sq ft of new space required in the UK for life science over the next decade<sup>(3)</sup>
- 6 Take-up at record highs – 1.4m sq ft recorded in the Golden Triangle from life science companies in 2022, the highest in the last 5 years<sup>(3)</sup>
- 7 Strong lab rental growth forecasts – 4.4% p.a. in Cambridge until 2027<sup>(5)</sup>



(6)




Note: Past performance is not indicative of future results

(1) HS stands for Herbrand Street; RSY stands for Rolling Stock Yard; CBP stands for Cambourne Business Park; OTP stands for Oxford Technology Park; LH stands for Lumen House and TMC stands for The Merrifield Centre; (2) UK Government Q4 2022 Research; (3) Savills Q4 2022 Research; (4) Cushman & Wakefield Q4 2022 Research; (5) Bidwells Q4 2022 Research; (6) The Economist July 2022 front cover


# UK LIFE SCIENCE SECTOR: LAB DEMAND EXCEEDS OFFICES FOR THE FIRST TIME

1.9m sq ft demand in the Oxford – Cambridge Arc, the highest ever recorded; 10% – 20% YoY rental growth across the Golden Triangle

Oxford – Cambridge Arc Lab Demand<sup>(1)</sup>



YoY Rental Growth<sup>(1)</sup>



# 03

## FINANCIAL RESULTS

For the year ended 31 December 2022

**£315.1m**  
EPRA NTA

**90.0p**  
EPRA NTA  
per share

**£2.5m**  
Adjusted  
Earnings

**0.7 pence**  
Adjusted  
Earning  
per share

**16.8%**  
LTV

**£65.2m**  
Net  
Borrowings<sup>(1)</sup>

Note: Past performance is not indicative of future results

(1) Excludes unamortised fees asset of £1.0m

## FINANCIAL RESULTS: +£2.8M EARNINGS VS PERIOD ENDED 31 DECEMBER 2021

£2.5m adjusted earnings driven by a full year's income of 2021 assets and c. 7 months of income of 2022 assets

Earnings for the 12 months / six weeks ended	31 December 2022	31 December 2021	YoY Change
Revenue, £m <sup>(1)</sup>	13.1	0.5	12.6
Property operating expenses, £m <sup>(1,2)</sup>	(2.2)	-	(2.2)
<b>Net rental income, £m</b>	<b>10.9</b>	<b>0.5</b>	<b>10.4</b>
Investment advisor fee, £m	(3.8)	(0.5)	(3.3)
Other administration expenses, £m	(1.8)	(0.3)	(1.5)
<b>Adjusted EBITDA, £m</b>	<b>5.3</b>	<b>(0.3)</b>	<b>5.6</b>
Net finance income / (costs), £m	(2.7)	-	(2.7)
Tax, £m	(0.1)	-	(0.1)
<b>Adjusted earnings, £m</b>	<b>2.5</b>	<b>(0.3)</b>	<b>2.8</b>
<b>Adjusted EPS, pence</b>	<b>0.7</b>	<b>(0.1)</b>	<b>0.8</b>
Dividend per share, pence <sup>(3)</sup>	4.0	-	4.0
Ongoing charges ratio, %	1.6	0.7	0.9

97% of  
rent collected

Property operating  
expenses primarily  
reflect void costs


Finance costs  
reflect the new  
HSBC facility plus  
debt acquired as  
part of OTP

Full year of  
trading in 2022

# FINANCIAL RESULTS: 10.2 PENCE REDUCTION IN NTAPS

£315.1m NTA / 90.0p NTA per share as at 31 December 2022

## Movement in NTA per share



# FINANCIAL RESULTS: £138.2M LIQUIDITY AS AT YEAR END; £73.6M PROFORMA

£110.8m debt drawn and acquired during 2022 resulting in LTV of 16.8%; Fairfield facility repaid post YE

## Key Financing & Liquidity Figures


	31-Dec-22	31-Dec-21
Net cash/(borrowings) <sup>(1)</sup>	(£65.2m)	£166.0m
Liquidity	£138.2m	166.0
Loan to value	16.8%	n/a
Gross loan to value	28.6%	n/a
ICR look back	119.0%	n/a
Debt maturity	1.8 yrs	n/a
WAIR	4.0%	n/a
SONIA hedging	94.1%	n/a

## Proforma Position post Q1 2023 Refinancing

	£m
Cash	45.6
Fairfield debt undrawn <sup>(3)</sup>	17.6
HSBC RCF undrawn <sup>(2)</sup>	75.0
<b>Liquidity at 31 December 2022</b>	<b>138.2</b>
Fairfield facility cancelled <sup>(4)</sup>	(54.1)
Second interim dividend	(10.5)
<b>Proforma liquidity</b>	<b>73.6</b>
<b>Proforma gross loan to value</b>	<b>26.1%</b>
<b>Proforma SONIA hedging (until Jun-23)</b>	<b>+104.3%</b>

## Debt Maturity Profile as at 31 December 2022

- HSBC term loan drawn
- HSBC term loan undrawn
- ▨ HSBC RCF
- OTP loan drawn
- OTP loan undrawn





# 04

## PORTFOLIO REVIEW

Resilient real estate and solid strategy

**8.7%**  
Inbuilt  
Reversion<sup>(1)</sup>

**+90.1%**  
Rental Upside  
from Existing  
Portfolio

Acquire Life  
Science Hubs in  
Key Locations

Reposition and  
Letting of Vacant  
Space to Life  
Science Uses

Active  
Management to  
Improve Hubs  
incl. Amenities

Leads to  
Increased Rental  
Tones and  
Capital Values

Note: Past performance is not indicative of future results

(1) Based on let area as at 31 December 2022

# PORTFOLIO REVIEW: SIGNIFICANT SUSTAINABILITY ACHIEVEMENTS IN 2022

Goals include reducing our impact on the environment and giving occupiers the best environment in which to thrive

★ 2023 Priority

## Environment

### 2022 Highlights

- Data collection and publication
- EPRA energy disclosures set up
- 247.1 tonnes CO2e - GHG emissions
- 155.0 MWh of electricity from PV panels
- 100% waste diverted from landfill
- BREEAM Excellent certificates achieved
- EPC ratings significantly improved

### Goals

- ★ Establish carbon targets and timeframe
- ★ Achieve BREEAM & EPC certifications
- ★ Biodiversity strategy on all projects
- Ensure water efficiency

## Social

### 2022 Highlights

- Stakeholder engagement with our occupiers and the Board
- Sponsored Cambourne's 10km run
- Provision made for local charity donation
- Conducted a local needs analysis for CBP

### Goals

- ★ Provide healthy buildings (Fitwel criteria)
- ★ Engage occupiers on the journey to net zero carbon and a healthy workforce
- Support local charitable organisations
- Provide space for collaboration
- Encourage active travel and provide cyclist facilities

## Governance


### 2022 Highlights

- Implemented a robust, fully functioning governance arm
- Established a Sustainability Committee
- Achieved an EPRA BPR Gold 2022 Award
- Undertaken a climate scenario analysis
- Integrated climate related risks into the risk framework

### Goals

- Oversight of ESG risks and opportunities
- Formalise sustainability governance
- Climate change mitigation
- Communicate via transparent disclosure and participate in benchmarks and indices

65% LFL increase in EPCs A-C since Dec-21<sup>(1)</sup>



Cambourne's 10k Run

2022 EPRA BPR Gold Award



# PORTFOLIO REVIEW: A GROWING PORTFOLIO

Portfolio can be broken down into two buckets: Investments and Developments

Overview as at 31 December 2022

## Investments

### Built (vs. Dec-21)

- 13 buildings (+4)
- 488,700 sq ft (+171,300 sq ft)
- £13.8m rent (+£4.5m)
- 82.0% occupied by 23 tenants (+1.0%)
- 6.2 yrs WAULT to expiry (-0.3 yrs)



Valuation: **£310.0m**

(+£117.8m vs Dec-21)

## Developments

### Development Property

- Buildings 4a, 4b and 5 onsite
- 125,900 sq ft
- PC in 2023
- £1.6m of rent pre-let or with terms agreed
- +60.0% of area with terms agreed



Valuation: **£41.2m**

### Land

- Buildings 6 – 11<sup>(1)</sup>
- Building 6 & 7 started onsite late Q3 2022
- 262,200 sq ft
- PC in 2024
- £5.2m future development ERV




Valuation: **£35.0m**

# PORTFOLIO REVIEW: +4.7% LFL ERV GROWTH YEAR ON YEAR

LFL ERV growth driven by lab conversion projects at Rolling Stock Yard and refurb initiatives at The Merrifield Centre

Asset Split by Valuation as at 31 December 2022



- Cambourne
- Rolling Stock Yard
- Herbrand Street
- OTP - Developments
- OTP - Investments
- Lumen House
- The Merrifield Centre

	Dec-22	Dec-21	Change
<b>ERV<sup>(1)</sup></b>	£17.2m	£10.1m	+70.5%
<b>LFL ERV</b>	£10.6m	£10.1m	+4.7%
<b>NIY</b>	4.2%	4.6%	-46bps
<b>NRY<sup>(1)</sup></b>	4.8%	5.0%	-23bps


# PORTFOLIO REVIEW: LIFE SCIENCE EXPOSURE INCREASING OVER TIME

Life science exposure to increase from 28% of contracted rent at year end to 42% as lettings under offer complete

## Life Science Exposure by Contracted Rent


	£m p.a.
Gyroscope Therapeutics	1.5
Carl Zeiss	1.0
The Native Antigen Company	0.5
Pacific Biosciences	0.5
Nanna Therapeutics	0.3
<b>Subtotal - Existing Occupiers</b>	<b>3.8</b>
<i>% of Total (Contracted Rent: £13.8m)</i>	<b>28%</b>
Williams Advanced Engineering	1.1
Syncona-owned business	0.8
Arcturis Data	0.2
Oxford Ionics	0.1
<b>Subtotal - Post YE</b>	<b>2.2</b>
<i>% of Total (Contracted Rent: £15.9m)</i>	37%
Deals Under Offer	1.2
<b>Subtotal - HoTs Agreed</b>	<b>1.2</b>
<i>% of Total (Contracted Rent: £17.2m)</i>	<b>42%</b>
<b>Total</b>	<b>7.2</b>

Dec-22



■ Life Science ■ Non-Life Science

Proforma to include deals signed post year end and deals under offer




■ Life Science ■ Non-Life Science

# PORTFOLIO REVIEW: H2 2022 VALUATIONS OUTPERFORMING OTHER SECTORS

6.3% H2 2022 absolute decline in valuation, significantly less than industrials, retail or offices

H2 2022 Absolute Movement in Valuations<sup>(1)</sup>



# PORTFOLIO REVIEW: ROLLING STOCK YARD

Gyroscope (a Novartis company), PacBio, and a Syncona group company all under the same roof in London's Knowledge Quarter

Office to Lab Conversion



Reception Refurb: The Co-lab



**ERV: £65.0 psf**

- 1<sup>st</sup> & 2<sup>nd</sup> floors vacant
- Office space with Dec-22 ERV of £65.0 psf
- To be repurposed to fully fitted labs



**Capex: £155.3 psf**

- Refurb of 1<sup>st</sup> & 2<sup>nd</sup> floors to fully fitted labs
- PC expected in Q1 2023
- Total project cost of £1.9m (£155.3 psf)




**ERV: £110.0 psf**

- 1<sup>st</sup> floor speculatively being fitted out
- 2<sup>nd</sup> floor pre-let prior to start on site
  - Pre-let to a Syncona group company

# PORTFOLIO REVIEW: OXFORD TECHNOLOGY PARK

Any configuration of office, labs, R&D and production space is possible, supported by necessary ancillary and storage space

Masterplan as at 27 March 2023



Building	% Let <sup>(1)</sup>	Estimated PC
1	66.8%	H1 2022
2	100.0%	H2 2021
3	100.0%	H1 2022
4a	n/a	H1 2023
4b	n/a	H1 2023
5	100.0% <sup>(2)</sup>	H1 2023
6	n/a	H2 2023
7	n/a	H2 2023
8	n/a	H1 2024
9	n/a	H2 2023
10	n/a	H1 2024
11	n/a	H2 2024

Completed

Under Construction

Land

1

2

3

4a

4b

5

6

7

8

9

10

11



[oxfordtechnologypark.com](http://oxfordtechnologypark.com)

# PORTFOLIO REVIEW: OXFORD TECHNOLOGY PARK (CONT'D)

Newly built campus coming to life and expected to reach PC in 2024



# PORTFOLIO REVIEW: CAMBOURNE BUSINESS PARK

## Transforming Cambourne Business Park into a modern Science and Technology Campus

### Masterplan



- 1<sup>st</sup> lab letting currently under offer
- Feasibility study concluded
  - Possibility of adding new buildings
  - Repositioning of vacant office space into labs
- Park rebranding under way to attract further life science occupiers

# PORTFOLIO REVIEW: +90% REVERSIONARY POTENTIAL

Rental upside to be captured through rent reviews, lease up of vacant space and development pipeline

Passing Rent to ERV Bridge as at 31 December 2022<sup>(1)</sup>



Note: Past performance is not indicative of future results

(1) HS = HS stands for Herbrand Street; RSY stands for Rolling Stock Yard; CBP stands for Cambourne Business Park; OTP stands for Oxford Technology Park; LH stands for Lumen House; (2) Assuming 82.0% occupancy; (3) Based on CBRE's ERVs

# 05

## CONCLUDING REMARKS

### Strong Life Science Sector

- Countercyclical to consumer trends
- Demand / supply imbalance
- Increasing government expenditure
- Increasing VC funding
- Positive outlook with take-up forecast to exceed pipeline

### LABS is Well Positioned

- High-quality well-located portfolio
- Attractive pipeline of assets
- Team's experience & industry contacts
- H2 2022 valuations resilient
- +90.1% reversionary potential
- 104.3% of SONIA debt hedged<sup>(1)</sup>
- Sustainability strategy developed
- Continue to roll out asset management strategies and driving up rental income



# 06

## APPENDICES

- 6.1 Management Agreements and Arrangements
- 6.2 UK Life Science Sector
- 6.3 Financial Results
- 6.4 Portfolio Review
- 6.5 Life Science REIT plc – Board of Directors
- 6.6 Ironstone Asset Management Ltd. – Investment Advisor
- 6.7 Life Science REIT plc – History

## APPENDIX 6.1: MANAGEMENT AGREEMENT AND ARRANGEMENTS


Investment Advisor	Ironstone Asset Management Ltd.
Fees	1.1% of NAV up to £500m; 0.9% of NAV between £500m - £1bn; 0.75% of NAV over £1bn. No performance fee or acquisition fee
Term	24 months' notice post four year anniversary of the date of admission
Board of Directors	Claire Boyle, Dr Sally Ann Forsyth OBE, Mike Taylor, Richard Howell
Listing	Investment company listing on the Main Market of the London Stock Exchange
Tax Status	UK REIT regime
AIFM	G10 Capital Ltd.
Strategy	Invest in a diversified portfolio of UK properties that are leased or intended to be leased to tenants operating in the life science sector
Target Total Accounting Return	+10% (Dividends plus NAV growth)
Target Dividend	REIT policy to distribute at least 90% of property income
Dividend Frequency	Half-yearly
NTA	EPRA NTA £315.1m or 90.0p per share as of 31 December 2022
Borrowings	£110.8m gross debt drawn at 31 December 2022. £150m debt facility with HSBC, comprising a £75m three-year term loan and a £75m RCF (225 bps over SONIA) and a £53.4m debt facility with Fairfield (712 bps over SONIA)
LTV	16.8% as at 31 December 2022
Target LTV	30.0% – 40.0%
Market Capitalisation	£212.8m as at 24 March 2023



## APPENDIX 6.2: VC FUNDING REACHES SECOND HIGHEST POINT IN HISTORY

Funding was down on 2021's figure, ultimately attributed to a weaker public market and to the fact that 2021 was a record year

VC Funding into Life Science Companies<sup>(1)</sup>



## APPENDIX 6.2: YIELDS EXPERIENCING AN OUTWARD SHIFT

Lab and office yields experienced an outward shift to 4.5% and 5.0% respectively following the increase in interest rates

Oxford Prime Yields<sup>(1)</sup>




Cambridge Prime Yields<sup>(1)</sup>




# APPENDIX 6.2: TAKE-UP IN THE NEXT 10 YEARS EXPECTED TO EXCEED PIPELINE

£15bn of capital looking for a home in UK life sciences real estate

Take-up Forecast up to 2031 (2022 – 2031)<sup>(1)</sup>



Pipeline up to 2030 (2022 – 2030)<sup>(2)</sup>



## APPENDIX 6.3: EPRA PERFORMANCE MEASURES

12 months/weeks ended	31 December 2022	31 December 2021
EPRA earnings, £m	1.5	(0.3)
EPRA EPS, pence	0.4	(0.1)
EPRA cost ratio (incl. void costs), %	66.3	163.5
EPRA cost ratio (excl. void costs), %	57.8	163.5
<b>As at</b>	<b>31 December 2022</b>	<b>31 December 2021</b>
EPRA NDV per share, pence	91.3	100.2
EPRA NRV per share, pence	95.9	103.9
EPRA NTA per share, pence	90.0	100.2
EPRA NIY, %	3.4	4.4
EPRA 'topped-up' NIY, %	3.6	4.5
EPRA vacancy rate, %	18.0	19.1
EPRA loan to value, %	18.9	n/a

## APPENDIX 6.3: BALANCE SHEET


16.8% LTV following new debt and debt acquired in year, target remains 30% - 40%

Balance sheet as at	31 December 2022	31 December 2021	YOY Change
Investment properties, £m	387.6	192.2	195.4
Net cash/(borrowings), £m	(65.2)	166.0	(231.2)
Other net liabilities, £m	(2.9)	(7.6)	4.7
<b>IFRS NAV, £m</b>	<b>319.5</b>	<b>350.6</b>	<b>(31.1)</b>
EPRA NTA adjustments, £m	(4.3)	-	(4.3)
<b>EPRA NTA, £m</b>	<b>315.1</b>	<b>350.6</b>	<b>(35.5)</b>
Number of shares, million	350.0	350.0	-
<b>EPRA NTA per share, pence</b>	<b>90.0</b>	<b>100.2</b>	<b>(10.2)</b>
Loan-to-value ratio	16.8%	n/a	16.8%
Dividends per share <sup>(1)</sup>	4.0% yield	n/a	-
Total accounting return	(9.1%)	n/a	(9.1%)

## APPENDIX 6.3: +£195.4M MOVEMENT IN VALUATIONS

The increase in valuations was driven by acquisitions and ongoing development and was partially offset by revaluation losses of £31.3m


### Movement in Valuations vs. Dec-21



## APPENDIX 6.3: ACQUISITIONS DRIVING INCREASE IN NET BORROWINGS

Remaining IPO proceeds and debt drawn in year utilised to fund acquisitions & drive asset management strategy

### Movement in Net Borrowings




## APPENDIX 6.4: STRONG OCCUPANCY DESPITE REPOSITIONING AND DEV'T

Construction activity progressed smoothly; two pre-lets signed months ahead of PC


Overview as at 31 December 2022

Asset	Valuation		Area sq ft	Occupancy %	WALUT to Break Years	WALUT to Expiry Years	Contracted Rent		NIY %	NRY %
	£m	£ per sq ft					£m p.a.	£ per sq ft		
Cambourne Business Park	87.2	376	231,700 <sup>(1)</sup>	80.1%	2.1	5.5	4.1	22.1	4.4%	5.8%
Rolling Stock Yard	83.9	1,558	53,900	66.7%	3.5	6.5	3.5	65.5	3.9%	4.6%
Herbrand Street	79.8	1,163	68,600 <sup>(1)</sup>	100.0%	--	3.8	4.0	58.5	4.7%	5.0%
Oxford Technology Park	43.8	420	104,300 <sup>(2)</sup>	72.5%	14.1	15.3	1.4	17.9	3.0%	5.1%
Lumen House	7.8	446	17,600	100.0%	--	0.4	0.4	24.5	5.1%	7.0%
The Merrifield Centre	7.5	595	12,600	100.0%	4.0	9.0	0.3	23.1	3.6%	5.5%
<b>Investment Assets</b>	<b>310.0</b>	<b>634</b>	<b>488,700</b>	<b>82.0%</b>	<b>4.5</b>	<b>6.2</b>	<b>13.8</b>	<b>33.1</b>	<b>4.2%</b>	<b>5.2%</b>
Oxford Technology Park - Developments	77.6	200	388,100	--	--	--	--	--	--	4.8% <sup>(3)</sup>
<b>Developments</b>	<b>77.6</b>	<b>200</b>	<b>388,100</b>	<b>--</b>	<b>--</b>	<b>--</b>	<b>--</b>	<b>--</b>	<b>--</b>	<b>4.8%</b>
<b>Total / Average</b>	<b>387.6</b>	<b>442</b>	<b>876,800</b>	<b>82.0%</b>	<b>4.5</b>	<b>6.2</b>	<b>13.8</b>	<b>33.1</b>	<b>4.2%</b>	<b>4.8%</b>


Asset Location by Valuation



Asset Type by Valuation<sup>(4)</sup>



Life Science Occupier Area by Floor Type<sup>(5)</sup>



## APPENDIX 6.4: NON-LIFE SCIENCE EXPOSURE POSITIVELY REDUCED

5 of the top 10 occupiers are now life science companies; tenant base to continue to transition over the next 12 months



### Top Ten Occupiers as at 31 December 2022

#	Name	Asset <sup>(1)</sup>	Rent p.a. (£m)	% of Total
1	Thought Machine	HS	4.0	29%
2	Gyroscope	RSY	1.5	11%
3	Carl Zeiss	CBP	1.0	7%
4	Xero (UK)	RSY	0.7	5%
5	Regus	CBP	0.7	5%
6	MTK Wireless	CBP	0.7	5%
7	Premier Inn	OTP	0.7	5%
8	The Native Antigen Company	OTP	0.5	4%
9	Pacific Biosciences	RSY	0.5	3%
10	Janet	LH	0.4	3%
<b>Subtotal – Top Ten</b>			<b>10.7</b>	<b>78%</b>
Remaining <sup>(2)</sup>			3.1	22%
<b>Total</b>			<b>13.8</b>	<b>100%</b>

### Pro Forma Top Ten Occupiers post YE<sup>(3)</sup> as at 27 March 2023

#	Name	Asset <sup>(1)</sup>	Rent p.a. (£m)	% of Total
1	Thought Machine	HS	4.0	25%
2	Gyroscope Therapeutics	RSY	1.5	10%
3	Williams Advanced Engineering	OTP	1.1	7%
4	Carl Zeiss	CBP	1.0	6%
5	Syncona-owned business	RSY	0.8	5%
6	Xero (UK)	RSY	0.7	4%
7	Regus	CBP	0.7	4%
8	MTK Wireless	CBP	0.7	4%
9	Premier Inn	OTP	0.7	4%
10	The Native Antigen Company	OTP	0.5	3%
<b>Subtotal – Top Ten</b>			<b>11.7</b>	<b>73%</b>
Remaining <sup>(2)</sup>			4.3	27%
<b>Total</b>			<b>15.9</b>	<b>100%</b>

## APPENDIX 6.5: LIFE SCIENCE REIT PLC BOARD OF DIRECTORS



### Claire Boyle

Chair and  
Non-Executive Director

Appointed as a Director of the  
Company on 14 October 2021

Claire is a NED and chair of the audit  
committee of Fidelity Special Values  
and Aberdeen Japan Investment  
Trust and a NED of The Monks  
Investment Trust

Over 20 years' experience working  
in financial services and investment  
management, having qualified as a  
chartered accountant with Coopers  
and Lybrand

Claire has a degree in Natural  
Sciences from Durham University



### Richard Howell

Audit and Risk Committee  
Chair and Senior Independent  
Non-Executive Director

Appointed as a Director of the  
Company on 3 May 2022

Richard is CFO of Primary Health  
Properties plc, the FTSE-250 REIT  
and leading investor in flexible,  
modern primary healthcare  
accommodation across the UK and  
Ireland

Over 20 years' of commercial  
property experience within the  
listed property sector

Richard is a qualified accountant  
and has a degree in Accounting and  
Finance from Kingston University



### Dr Sally Ann Forsyth OBE

Non-Executive Director

Appointed as a Director of the  
Company on 14 October 2021

Sally Ann is CEO of the Stevenage  
Bioscience Catalyst and is a pioneer  
of the Life Science real estate  
industry with over 16 years of  
experience delivering outstanding  
science parks

Sally Ann has a PhD in molecular  
biology from the University of  
Cambridge, a certificate in Real  
Estate Economics and Finance from  
LSE and is a qualified management  
accountant (CGMA)

She was awarded an OBE for  
services to Business and Science in  
2021



### Mike Taylor


Management Engagement  
Committee and  
Remuneration Committee  
Chair and Non-Executive  
Director

Appointed as a Director of the  
Company on 14 October 2021

Mike is a Commercial Director for  
the British Heart Foundation (the  
"BHF"), where he is responsible for  
their commercial revenues across  
720 retail outlets, online channels  
and commercial health ventures,  
with annual revenues of over  
£200m. The BHF funds Life Science  
research into heart and circulatory  
diseases

Mike has a degree in Economics  
from the University of East Anglia

# APPENDIX 6.6: IRONSTONE ASSET MANAGEMENT LTD. INVESTMENT ADVISOR





## APPENDIX 6.7: LIFE SCIENCE REIT PLC HISTORY

### Timeline of Key Events



